Isolated jaw periosteum-derived cells (JPCs) comprise a morphologically heterogeneous population. There are no known specific surface markers that are able to distinguish between progenitors and cells of other tissue types. The aim of our study was to identify differentiation markers as predictors of JPC mineralization capacity. JPCs underwent osteogenic differentiation after cultivation in osteogenic medium containing known activators. By FACS analysis, we found the low affinity nerve growth factor receptor (LNGFR-CD271) to be induced during the first five days of osteogenesis and that it was expressed at higher levels in mineralizing JPCs (mJPCs) in comparison to non-mineralizing JPCs (nmJPCs). Similar results were obtained by semi-quantitative immunohistochemical stainings and western blot analyses. Quantitative real-time PCR results showed significantly higher LNGFR and alkaline phosphatase transcript levels in mJPCs compared to nmJPCs. LNGFR is a differentiation marker that distinguishes between mineralizing JPCs and non-mineralizing JPCs during the first phase of osteogenesis and can therefore be considered an early surface marker of osteogenic capacity in vitro.
Introduction
For bone tissue engineering applications different mesenchymal stem cell sources could be used, however depending on their localization they show different expression profiles [1] [2] [3] . Despite the fact that jaw periosteum-derived cells (JPCs) have some advantages over bone marrow-derived mesenchymal stem cells (BMMSCs) for applications in oral and maxillofacial surgery [1] , they are still poorly characterized and little is known about their antigenic profile and differentiation behaviour. JPCs have a specialized function within the jaw and their localization commonly overlaps with the site of oral or maxillofacial surgery. The osteogenic potential of tibial periosteum-derived cells remains the same as age increases [4] . This is not the case for BMMSCs, which are known to lose their osteogenic potential with increases in age [5] . The osteogenic potential and bone capacity of BMMSCs in comparison 284 to isogenic JPCs was already investigated [2] . The results showed a delayed and overall reduced capacity of JPCs to differentiate toward the osteoblastic lineage as compared to BMMSCs [2] . However, a recently published work demonstrated an effective tissue engineering using periosteal cells [1] .
The low-affinity nerve growth factor receptor (LNGFR), also referred to as the p75 neutrophin receptor (p75 NTR ), tumor necrosis factor receptor superfamily member 16 (TNFRSF16) or CD271, was described as the most selective marker for the purification and phenotypic characterization of BMMSC [6] . LNGFR, is a transmembrane protein capable of binding nerve growth factor [7] . Whereas LNGFR binds to the precursors of neurotrophic factors with low affinity, it is required for efficient Trk kinase activation and signaling [7] . LNGFR also has been proven to be an useful marker for the isolation of adipose tissue-derived stem cells in a mouse animal model [8] .
After JPC isolation, a heterogeneous cell population containing several cell types is obtained. We found two cell groups that act differently during osteogenesis: one cell group is not able to mineralize in vitro (non-mineralizing JPCs-nmJPCs), and the other cell group is able to mineralize in vitro (mineralizing JPCs-mJPCs). As specific markers that distinguish between progenitor and other cell types are currently lacking, we aimed to identify predictors of JPC osteogenic capacity in order to improve the quality of this stem cell type for bone regeneration.
In the present study, we detected a significant elevation of the cell surface marker LNGFR (CD271) in osteogenic differentiated JPCs during the first five days of osteogenesis.
Materials and Methods

Cell cultures
Biopsies of human jaw periosteum were obtained during routine maxillofacial interventions. Samples from 14 donors were included in the study in accordance with the local ethical committee, following informed consent. JPCs were isolated in a predigestion step by type XI collagenase (1500 U/ml, Sigma, Steinheim, Germany) and dispase II (2.4 U/ml, Roche Applied Sciences, Mannheim, Germany) in a 1:1 mixture for 30 min. The main digestion step followed for 90 min with type XI collagenase.
JPCs were cultured in D-MEM: F-12 (InvitrogenBioSource Europe, Nivelles, Belgium) containing 10% FCS (Sigma-Aldrich, Steinheim, Germany), 100 U/ml penicillin/ streptomycin (Cambrex, Walkersville, USA) and 50 µg/ml fungicide (Biochrom AG, Berlin, Germany). Periosteal cells from the third to sixth passages were used for these experiments.
After isolation of quite a few patient JPCs, we always obtained a mixed and heterogenous cell population containing different cell types (tissue fibroblasts and others) and probably different stages of possible progenitor cells. A reliable separation of the outer (fibrous tissue) from the inner layer (cambium layer containing the progenitor cells) of periosteum was not possible. On the basis of our results and with respect to their osteogenic potential, we classified the isolated and expanded cells afterwards into two groups: 1) non-mineralizing JPCs (nmJPCs), which were not able to calcify in vitro (n=7) and 2) mineralizing JPCs (mJPCs), which were able to calcify in vitro (n=7). JPC mineralization was detected by alizarin staining. nmJPCs showed an alizarin-negative staining after 20 days of osteogenesis (percentage of mineralization 0%). mJPCs clearly showed an alizarin-positive (reddish dye) staining after the same period of osteogenic differentiation (percentage of mineralization 50-90%). Cell cultures with lower mineralization potential were not included in the study. However, these two cell culture types were derived from different and not the same donors. We did not detect clear morphological differences between nmJPCs and mJPCs, which would make a simple morphological differentiation between both cell types practicable.
Differentiation experiments
For the osteogenic differentiation experiments, mJPCs and nmJPCs were cultured in D-MEM/10% FCS, 4 µM dexamethasone, 10 mM -glycerolphosphate and 100 µM Lascorbic acid 2-phosphate (Sigma-Aldrich, Germany). Cells were treated with these components for a period of 20 days in the absence (referred to as OB-medium) or presence of 100 ng/ml human recombinant BMP-2 (referred to as OB/BMP-2). The culture medium was replaced every two days. As controls, we used untreated JPCs that were cultivated in the absence of any osteogenic components for the same time period.
Alizarin and von Kossa staining
Calcium deposition of JPCs was detected by alizarin staining. Therefore, cells were fixed in ice-cold methanol for 2 min, air-dried and stained with alizarin for 20 min. Differentiated cells containing mineral deposits were stained bright red. The JPC mineralization capacity was also detected by an alternative method, von Kossa silver staining. Fixed cells were incubated with 5% silver nitrate solution for one hour in the dark. Reduction with sodium carbonate and fixation with 5% sodium thiosulfate followed for 2 min.
RNA extraction and quantitative RT-PCR
Total cellular RNA was extracted from differentiated cells and untreated controls using the RNeasy Mini Kit (Qiagen, Hilden, Germany) as recommended by the manufacturer. Firststrand cDNA for the real-time PCR experiments was synthesized by reverse transcription at 42°C in a 20 µl reaction mixture containing 1 µg of total RNA. After heating the samples at 95°C for 10 min for denaturation and cooling to 4°C, cDNA was used for PCR amplification. Reactions were diluted to 100 µl with DEPC-treated water. To quantify mRNA expression, real-time PCR with the LightCycler System (Roche Diagnostics, Mannheim, Germany) was performed (for detail [9] ). PCRs for all analysed genes were performed in 20 µl final volumes of containing 2 µl cDNA, 2 µl primer mix (commercial primer kits from Search LC, Heidelberg, Germany), 2 µl DNA Master Sybr Green I mix (Roche Molecular Biochemicals, Mannheim, Germany) and 14 µl DEPC-treated water. Amplification of the target DNA was performed during 35-38 cycles of 95°C for 10 s, 68°C for 10 s and 72°C for 16 s, each with a temperature transition rate of 20°C/s and a secondary target temperature of 58°C with a step size of 0.5°C. Melting curve analysis was performed at 95°C 0 s, 58°C 10 s, 95°C 0 s to allow discrimination between unspecific primer dimers and specific PCR products. The transcript levels of the housekeeping gene GAPDH and alkaline phosphatase (AP), osterix (Osx), Runx-2 (Cbfa1) and insulin-like growth factor-2 (IGF-2) were also determined for each sample using a commercial primer kit (Search LC, Heidelberg, Germany). Finally, results were calculated as a ratio of the target versus the housekeeping gene transcripts.
Analysis of LNGFR protein expression
LNGFR immunohistochemistry was performed after fixation of cells in ice-cold methanol for 5 min. After a hydrogen peroxide block for 7 min and an additional wash step with PBS, cells were incubated with the monoclonal mouse antibody anti-LNGFR (ME20.4, 1:500, Santa Cruz Biotechnology, USA) for 1.5 hours at room temperature. For the following steps, the NOVA Detect HRPO/DAB Quick Kit (Dianova, Germany) was used.
For western blot analysis pelleted cells were dissolved in 60 µl lysis buffer (1% NP40; 150 mM NaCl; 50 mM Tris/HCL, pH 8.0 plus protease inhibitors) which were stored overnight at -70°C. Cell debris were removed by centrifugation and protein concentrations of the supernatants were measured using a colorimetric assay (RD DC Protein Assay, BioRad, Germany). After addition of reducing Laemmli sample buffer, a total of 50 µg of nondenaturated cell lysate from the cellular extracts was separated by SDS-PAGE (10%) and transferred onto nitrocellulose membranes. The membranes were analyzed by immunoblotting using monoclonal mouse anti-LNGFR (ME20.4 1:1000, Santa Cruz, USA) and anti-GAPDH (Abcam, UK) specific primary antibodies overnight at 4°C. Binding of the primary antibodies was detected with peroxidase-conjugated goat antimouse secondary antibodies (Santa Cruz, USA) and visualized by the enhanced chemiluminescence method (GE Healthcare, Germany).
Flow cytometry analysis of LNGFR
After cell detachment with 0.5% trypsin and washing with PBS, cell pellets were incubated with 60 µl GAMUNEX 10% (human immune globulin solution) for 15 min at 4°C to block unspecific labelling. After an additional wash step, up to 10 4 cells were incubated with 10 µl mouse monoclonal antibodies conjugated to allophycocyanin (CD271-APC, mouse IgG1, clone ME20.4-1H4, Miltenyi Biotec, Germany) for 15 min at 4°C. Cells were washed twice with FACS buffer (PBS/1% BSA/ 0.01% NaN 3 ) and analysed on a FACSCanto flow cytometer (Becton Dickinson, Germany). Data were processed using the FCS Express software (DeNovo, Canada).
Statistical analysis
Data are expressed as means ± SEM. Statistical analysis was performed using non-parametric paired t-tests for data with a normal distribution. A value of p< 0.05 was considered significant. LNGFR Induction During JPC Osteogenesis Fig. 1 . Osteogenic potential of jaw periosteal cells. Periosteal cells underwent osteogenesis (OB=osteoblast specific medium, OB/BMP-2=osteoblast specific medium and BMP-2) and mineralization potential was tested after 20 days of differentiation by the alizarin (upper panel) and von Kossa (lower panel) staining (magnification 4x) in comparison to untreated cells (co=control cells). We found two cell groups: mineralizing JPCs (mJPCs) and nonmineralizing JPCs (nmJPCs). Detected calcium-phosphate precipitates formed from JPCs, resulting in a reddish staining after addition of alizarin and in a black staining after silver staining. Negative staining was observed in untreated and OB/OB-BMP-2 nmJPCs.
Results
Osteogenic potential of JPCs
The mineralization capacity of differentiating JPCs was determined after 20 days of culture using alizarin and von Kossa stainings. We classified the isolated and expanded cells into two groups: non-mineralizing JPCs Fig. 2A) and LNGFR (Fig. 2B) gene expression was quantified in mJPCs/nmJPCs (n=7 for each group) at days 5, 10 and 20 of osteogenesis by real-time PCR. Ratios of AP or LNGFR/GAPDH are denoted in the y-axis. * p<0.05. Significantly elevated AP transcript levels were detected in mJPCs versus nmJPCs at all analysed time points (days 5, 10, 20) in both untreated controls and differentiating cells. Significantly elevated LNGFR transcript levels were found in OB-treated mJPCs vs. nmJPCs. The same tendency of higher LNGFR gene expression was observed in OB/BMP-2-treated mJPCs vs. nmJPCs, however, the differences achieved no significant values.
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(nmJPCs, n=7), which were not able to calcify in vitro and mineralizing JPCs (mJPCs, n=7), which developed strong reddish staining with containing calcium-phosphate precipitates ( Fig. 1 upper panel) . Similarly, von Kossa silver staining of nmJPCs resulted in a negative reaction, whereas calcium-precipitates formed in mineralizing JPCs, resulting in a black staining (Fig. 1, lower panel) . 
Gene expression analyses of AP and LNGFR in mJPCs versus nmJPCs
Expression levels of alkaline phosphatase were significantly elevated in mJPCs versus nmJPCs in both untreated and osteogenic differentiating cells (Fig. 2A) .
LNGFR Induction During JPC Osteogenesis nmJPCs also responded to the osteogenic stimuli with an induction of AP gene expression, however, the levels were significant lower than those detected in mJPCs. At day 5, we found higher AP/GAPDH ratios in untreated mJPCs (13.87±3.41) compared to untreated nmJPCs A B Fig. 3 . LNGFR protein expression in mJPCs vs. nmJPCs. mJPCs/nmJPCs underwent osteogenesis and LNGFR protein expression was detected after day 20 by immunohistochemistry (Fig.  3A, magnification 4x) or by Western blotting (Fig. 3B) . As a positive control, whole cell lysates from human neuroepithelioma cells were used. As loading controls, GAPDH protein expression was detected in the same lysates. Representative stainings/ blots for mJPCs and nmJPCs are illustrated. (2.85±0.83). This difference was highly significant (p<0.01) and remained almost the same at day 10 and day 20. Five days after initiation of osteogenesis, we detected in OB-and OB/BMP-2 treated mJPCs strongly elevated AP/GAPDH ratios (53.57±12.05 and 53.44±10.79, respectively), which were significantly higher than those in OB-and OB/BMP-2 treated nmJPCs (5.96±2.2 and 7.17±1.24, respectively). Likewise, we found at day 10 and day 20 of differentiation significantly higher AP levels in OB-and OB/BMP-2 treated mJPCs.
LNGFR gene expression was analyzed by quantitative real-time PCR in mJPCs versus nmJPCs at days 5, 10 and 20 of osteogenesis (Fig. 2B) . At all analyzed time points, OB-and OB/BMP-2 treated mJPCs (n=7) showed higher LNGFR transcript levels than nmJPCs (n=7, Fig. 2B ). At the first analyzed time point (day 5), transcript levels of LNGFR were slightly, but significantly increased in untreated controls from mJPCs versus nmJPCs (mJPCs: 0.23±0.05; nmJPCs 0.09±0.02). Induction of osteogenesis led to higher LNGFR/GAPDH ratios by day 5 in OB-and OB/BMP-2 treated mJPCs LNGFR protein expression in mJPCs versus nmJPCs LNGFR protein expression was analyzed at the same time points as chosen for quantitative PCR analysis (days 5, 10 and 20 of osteogenesis). After initiation of osteogenesis in JPCs, protein levels of LNGFR were detected by immunohistochemistry. A slight induction of LNGFR protein expression was already observed at the beginning of differentiation (day 5, data not shown), which gradually increased through the end of osteogenesis in mJPCs at day 20 (Fig. 3A) .
Similar to the quantitative PCR results, an induction of LNGFR expression was also detected by western blot with gradually increasing intensity during osteogenesis in OB-and OB/BMP-2 treated mJPCs (Fig. 3B) . When results from mJPCs were compared with those from nmJPCs, much stronger signals could be detected in the mJPCs group.
Flow cytometry analysis of LNGFR expression in mJPCs versus nmJPCs
LNGFR expression on cell surface was detected by FACS analysis at the beginning of osteogenesis. Representative histograms for LNGFR expression in mJPCs (n=6) versus nmJPCs (n=6) after day 5 of osteogenesis are illustrated in Fig. 4A . In untreated mJPCs we found on average 44% LNGFR positive cells, whereas nmJPCs were shown to be on average 60% positive for LNGFR. However, FACS analysis showed a particular pattern of LNGFR expression in osteogenic differentiated JPCs. Due to OB or OB/BMP-2 treatment of mJPCs, cells showed a LNGFR bright expression which reflects a LNGFR induction (on average 62%) during osteogenesis. OB or OB/BMP-2 treated nmJPCs revealed a LNGFR dim expression which indicates a repression of LNGFR presentation on cell surface (on average 49% and 45% respective).
Analysis of the median fluorescence intensity revealed significantly higher levels of LNGFR expression in OB-treated mJPCs than in OB-treated nmJPCs after initiation of osteogenesis (day 5: OB-treated mJPCs 1.81±0.28 versus OB-treated nmJPCs 0.86±0.03, p<0.01, Fig. 4B ). The same tendency was observed in OB/BMP-2-treated cells, however, the differences were not considered significant.
Discussion
Despite the fact that isolated jaw periosteum-derived cells (JPCs) could be used for bone tissue applications, these cells represent a morphologically heterogeneous population. Furthermore, due to the unavailability of specific markers for JPCs, we run the risk of other cell types outgrowing progenitor cells, resulting in the culturing of a cell population that lacks progenitor cells. Our observation that not all isolated JPCs are able to mineralize in vitro could be due to the concomitance of different cell types, which might interfere with the complex mineralization process. For isolation and characterization of bone marrow-derived mesenchymal stem cells (BMMSCs) [10] and of adipose tissue-derived stem cells [8] the low-affinity nerve growth factor receptor (LNGFR) is one of the key markers. In previous studies the expression of LNGFR and alkaline phosphatase (AP) was almost undetectable in undifferentiated tibial periosteal cells [11] . These results are in line with our data in undifferentiated control JPCs. In the present work, we identified LNGFR transcripts to be differentially modulated within the first five days of JPCs osteogenic differentiation process. Furthermore, western blot data demonstrate higher protein levels of LNGFR in mineralizing JPCs (mJPCs) compared to non-mineralizing JPCs (nmJPCs) at this early time point. A similar pattern on transcript and protein levels can be found at day 10 and day 20. These results indicate a role for LNGFR as an earlier marker for JPC mineralization capacity than the Alizarin or von Kossa stainings, which are useful only after 20 days of differentiation. LNGFR is a surface marker which could be used for isolation procedures. In general, by FACS analysis LNGFR showed nearly an opposite pattern of expression in OB-and OB/BMP-2 treated mJPCs in contrast to identical treated nmJPCs. Other groups has been investigated LNGFR in different settings. Recently, LNGFR positive cells were isolated from the growth zones of regenerating fallow deer antlers as well as the pedicle periosteum [12] . The alteration of LNGFR expression following differentiation has been investigated also in mesenchymal stem cells [13] . This group differentiated MSCs along a Schwann cell lineage and showed that LNGFR expression was strongly elevated upon differentiation [13] .
LNGFR was shown to modulate the expression of genes that are critically involved in the regulation of differentiation as well as cell adhesion, signal transduction, apoptosis, tumor cell invasion, and metastasis [14] . Numerous adaptor proteins that bind LNGFR have been reported [15] . Increased LNGFR levels were found to be associated with reduced levels of MMP-9 and increased levels of TIMP-1 [16] . Re-expression of lost LNGFR in prostate cancer cells appeared to partially reverse the de-differentiation of tumor cells [14] . This could be related to up-regulation of the retinoic acid receptors (RAR) and increased cellular retinoic acid-binding protein I (CRABPI) levels for localized sequestration of retinoids, as retinoic acid has been shown to stimulate osteogenic differentiation of stem cells [17] . LNGFR could modulate osteogenesis through the increase of RAR and CRABPI however, this is unlikely to be the only mode of action.
Taken together, JPCs represent an alternative to bone marrow-derived mesenchymal stem cells (BMMSCs) for tissue engineering applications. Looking at our results, one can state that jaw periosteum-derived cell cultures showing high LNGFR expression during the first five days of osteogenesis will have a greater probability to mineralize at day 20 than cultures without showing a strong induction of LNGFR expression. This merely indicates a higher osteogenic capacity in mJPC versus nmJPC probably based on the majority of osteoprogenitors. LNGFR can therefore be considered an early surface marker of osteogenic capacity in vitro. However, LNGFR could not be allocated to a distinct type of osteoprogenitor cell which surely exist in our cultures. To date we do not know whether in our case LNGFR really mark mesenchymal osteoprogenitors or if our cultures contain other LNGFR-positive cells which might be essential to initiate or enhance the capacity of progenitors towards osteogenic differentiation. Further analysis of the in vivo relevance of LNGFR for the osteogenic process has to be done. 
